Related Experiment Video
Updated: Jun 19, 2026
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Mesenchymal stromal cells for cardiovascular repair: current status and future challenges
Anders Bruun Mathiasen1, Mandana Haack-Sørensen, Jens Kastrup
1Cardiac Stem Cell laboratory & Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, Copenhagen University Hospital & Faculty of Health Sciences, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. abbe@mail.dk
Insights
Stem cell therapy, particularly using mesenchymal stromal cells, shows promise for regenerating heart tissue and improving cardiac function in patients with ischemic heart disease. Further research is needed to address remaining questions in cardiovascular regenerative medicine.
Area of Science:
- Cardiovascular Regenerative Medicine
- Stem Cell Therapy
- Myocardial Regeneration
Background:
- Ischemic heart disease remains a leading cause of mortality globally.
- Current treatments for heart failure have limitations, with a significant 1-year mortality rate.
- Stem cell therapy offers a novel approach for myocardial regeneration.
Purpose of the Study:
- To review current preclinical and clinical knowledge on stem cell use in cardiovascular regenerative medicine.
- To focus on mesenchymal stromal cells as a promising source for cardiac regeneration.
- To examine stem cell sources, delivery methods, and tracking techniques.
Main Methods:
- Review of preclinical and clinical studies on stem cell therapy for cardiac regeneration.
- Focus on mesenchymal stromal cells (MSCs).
- Exploration of stem cell sources, delivery, and tracking.
Main Results:
- Clinical studies indicate significant improvements in ventricular function, remodeling, perfusion, and symptoms with stem cell therapy.
- Mesenchymal stromal cells show potential for regenerative therapy in the heart.
- Promising results observed compared to conventional treatments.
Conclusions:
- Stem cell therapy, especially with MSCs, holds significant promise for treating ischemic heart disease and heart failure.
- Further investigation is required to answer outstanding questions in the field.
- Optimizing stem cell sources, delivery, and tracking is crucial for clinical success.
Abstract:
Ischemic heart disease is the most common cause of death in most industrialized countries. Early treatment with stabilizing drugs and mechanical revascularization by percutaneous coronary intervention or coronary bypass surgery has reduced the mortality significantly. In spite of improved offers of treatments in patients with heart failure, the 1-year mortality is still approximately 20% after the diagnosis has been established. Treatment with stem cells with the potential to regenerate the damaged myocardium is a relatively new approach. Mesenchymal stromal cells are a promising source of stem cells for regenerative therapy. Clinical studies on stem cell therapy for cardiac regeneration have shown significant improvements in ventricular pump function, ventricular remodeling, myocardial perfusion, exercise potential and clinical symptoms compared with conventionally treated control groups. The results of most studies are promising, but there are still many unanswered questions. In this review, we explore present preclinical and clinical knowledge regarding the use of stem cells in cardiovascular regenerative medicine, with special focus on mesenchymal stromal cells. We take a closer look at sources of stem cells, delivery method and methods for tracking injected cells.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...